Charles River Laboratories International, Inc. (NYSE:CRL) Expected to Post Quarterly Sales of $1.01 Billion

Wall Street brokerages forecast that Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) will report $1.01 billion in sales for the current quarter, Zacks reports. Six analysts have issued estimates for Charles River Laboratories International’s earnings, with the highest sales estimate coming in at $1.03 billion and the lowest estimate coming in at $962.90 million. Charles River Laboratories International posted sales of $914.61 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 10.4%. The company is expected to report its next earnings results on Monday, January 1st.

On average, analysts expect that Charles River Laboratories International will report full year sales of $4.05 billion for the current year, with estimates ranging from $4.02 billion to $4.07 billion. For the next fiscal year, analysts forecast that the company will post sales of $4.50 billion, with estimates ranging from $4.40 billion to $4.56 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that cover Charles River Laboratories International.

Charles River Laboratories International (NYSE:CRLGet Rating) last issued its quarterly earnings data on Wednesday, May 4th. The medical research company reported $2.75 EPS for the quarter, topping the consensus estimate of $2.71 by $0.04. The business had revenue of $913.93 million for the quarter, compared to the consensus estimate of $908.64 million. Charles River Laboratories International had a return on equity of 21.90% and a net margin of 11.64%. The firm’s revenue was up 10.8% compared to the same quarter last year. During the same quarter last year, the business posted $2.53 EPS.

Several analysts recently commented on CRL shares. Jefferies Financial Group downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $370.00 to $280.00 in a research note on Monday, April 25th. Wells Fargo & Company lowered their target price on Charles River Laboratories International from $390.00 to $325.00 and set an “overweight” rating for the company in a report on Monday, April 25th. KeyCorp lowered their target price on Charles River Laboratories International from $390.00 to $300.00 in a report on Thursday, May 5th. UBS Group lowered their target price on Charles River Laboratories International from $465.00 to $420.00 and set a “buy” rating for the company in a report on Thursday, February 17th. Finally, Morgan Stanley lowered their target price on Charles River Laboratories International from $465.00 to $430.00 and set an “overweight” rating for the company in a report on Thursday, February 17th. Five investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Buy” and a consensus target price of $387.88.

Charles River Laboratories International stock traded up $9.10 during mid-day trading on Monday, hitting $235.81. 470,228 shares of the company’s stock were exchanged, compared to its average volume of 683,400. The firm has a market capitalization of $11.98 billion, a P/E ratio of 28.72, a PEG ratio of 1.37 and a beta of 1.27. Charles River Laboratories International has a fifty-two week low of $217.20 and a fifty-two week high of $460.21. The company has a quick ratio of 1.12, a current ratio of 1.34 and a debt-to-equity ratio of 1.02. The company’s 50 day simple moving average is $269.49 and its 200-day simple moving average is $322.65.

In related news, Director George Massaro sold 178 shares of Charles River Laboratories International stock in a transaction that occurred on Monday, May 9th. The stock was sold at an average price of $230.96, for a total transaction of $41,110.88. Following the completion of the sale, the director now directly owns 4,677 shares of the company’s stock, valued at approximately $1,080,199.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO James C. Foster sold 20,000 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, February 15th. The stock was sold at an average price of $315.46, for a total value of $6,309,200.00. The disclosure for this sale can be found here. Insiders have sold a total of 39,153 shares of company stock valued at $11,832,257 over the last quarter. 1.10% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC lifted its holdings in Charles River Laboratories International by 27.0% during the 1st quarter. Renaissance Technologies LLC now owns 34,409 shares of the medical research company’s stock worth $9,771,000 after purchasing an additional 7,309 shares during the last quarter. Ariel Investments LLC lifted its holdings in Charles River Laboratories International by 16.8% during the 1st quarter. Ariel Investments LLC now owns 209,795 shares of the medical research company’s stock worth $59,575,000 after purchasing an additional 30,148 shares during the last quarter. Bellevue Group AG raised its holdings in Charles River Laboratories International by 91.8% in the 1st quarter. Bellevue Group AG now owns 126,406 shares of the medical research company’s stock valued at $35,896,000 after acquiring an additional 60,495 shares in the last quarter. ING Groep NV raised its holdings in Charles River Laboratories International by 21.5% in the 1st quarter. ING Groep NV now owns 8,006 shares of the medical research company’s stock valued at $2,273,000 after acquiring an additional 1,419 shares in the last quarter. Finally, Ancora Advisors LLC raised its holdings in Charles River Laboratories International by 98.4% in the 1st quarter. Ancora Advisors LLC now owns 20,846 shares of the medical research company’s stock valued at $6,042,000 after acquiring an additional 10,341 shares in the last quarter. 93.06% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile (Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Featured Articles

Get a free copy of the Zacks research report on Charles River Laboratories International (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.